S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

about

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).

Item

http://www.wikidata.org/entity/Q49561302

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

S2k Guidelines - Cutaneous Lym ...... d Follow-up (ICD10 C82 - C86).

@en

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up

@nl

type

Item

label

S2k Guidelines - Cutaneous Lym ...... d Follow-up (ICD10 C82 - C86).

@en

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up

@nl

prefLabel

S2k Guidelines - Cutaneous Lym ...... d Follow-up (ICD10 C82 - C86).

@en

S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up

@nl

P1476

S2k Guidelines - Cutaneous Lym ...... d Follow-up (ICD10 C82 - C86).

@en

P2093

Antonio Cozzio

http://www.w3.org/2001/XMLSchema#string

Carmen Loquai

http://www.w3.org/2001/XMLSchema#string

Chalid Assaf

http://www.w3.org/2001/XMLSchema#string

Christoph Stoll

http://www.w3.org/2001/XMLSchema#string

Claus-Detlev Klemke

http://www.w3.org/2001/XMLSchema#string

Cristina Lamos

http://www.w3.org/2001/XMLSchema#string

Dominik Mestel

http://www.w3.org/2001/XMLSchema#string

Dorothee Nashan

http://www.w3.org/2001/XMLSchema#string

Edgar Dippel

http://www.w3.org/2001/XMLSchema#string

Frank Meiß

http://www.w3.org/2001/XMLSchema#string

P2860

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

The optimal use of bexarotene in cutaneous T-cell lymphoma

Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches.

Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.

Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

P304

112-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DDG.13401

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29280595

http://www.w3.org/2001/XMLSchema#string